Since these data provide a rationale to combine DEX and imatinib with ABT-199 in BCR-ABL + ALL, we examined a potentially synergistic action of ABT-199, dexamethasone, and imatinib by dose-effect combination index (CI) analysis. Here, ABL1 is linked to acute lymphoblastic leukemia.